Rigel Pharmaceuticals Reports Q3 2026 Results Driven by VEPPANU Launch and REZLIDHIA Growth
Rigel Pharmaceuticals (RIGL) reported third-quarter 2026 net product sales of $72.3 million, a 13% increase year-over-year. This growth was primarily fueled by the successful commercial introduction of VEPPANU following its August launch and continued expansion of REZLIDHIA in community oncology settings. While TAVALISSE revenue saw a modest 3% uptick due to high U.S. demand, GAVRETO revenues declined by 11% compared to the previous year. The company narrowed its full-year total revenue guidance to a range of $290 million to $295 million. Despite top-line growth, net income fell to $13.2 million from $27.9 million in the prior year period, largely due to increased research and development spending and costs associated with the VEPPANU commercial launch. Rigel maintains a cash position of $99.3 million as it continues clinical development for R289.
Topics: Guidance Update Net Product Sales Product Launch Revenue Growth